Potential Role of Type I Interferons in the Treatment of Pituitary Adenomas

Overview

Journal Rev Endocr Metab Disord

Publisher Springer

Specialty Endocrinology

Date 2008 Jul 8

PMID 18604644

Citations 2

Authors

Giovanni Vitale

Michele Caraglia

Peter M Van Koetsveld

Paola Maroni

Monica Marra

Annamaria Colao

Steven W J Lamberts

Francesco Cavagnini

Leo J Hofland

Affiliations

Soon will be listed here.

Abstract

Cytokines, particularly those endowed with pro-inflammatory properties, are known to influence the release of anterior pituitary hormones by a direct and indirect action at the level of pituitary gland and hypothalamus. Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies underline the fact that type I IFNs are involved in the regulation of the immune-endocrine circuitry. Treatment with type I IFNs of patients affected by chronic viral hepatitis, multiple sclerosis and tumors influences the secretion of pituitary hormones. This article reviews the current knowledge about the effects of IFN-alpha and IFN-beta on hypothalamic-pituitary function and describes the potential role of type I IFNs in the treatment of pituitary adenomas.

Citing Articles

Pituitary side effects of old and new drugs.

Zatelli M, Ambrosio M, Bondanelli M, Degli Uberti E J Endocrinol Invest. 2014; 37(10):917-23.

PMID: 25070042 DOI: 10.1007/s40618-014-0133-2.

HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies.

Trovato M, Torre M, Ragonese M, Simone A, Scarfi R, Barresi V Endocrine. 2013; 44(3):735-43.

PMID: 23576023 DOI: 10.1007/s12020-013-9950-x.

References

Colao A, Pivonello R, Cappabianca P, Vitale G, Lombardi G . The treatment algorithm of acromegaly. J Endocrinol Invest. 2004; 26(8 Suppl):39-45. View

Gillam M, Molitch M, Lombardi G, Colao A . Advances in the treatment of prolactinomas. Endocr Rev. 2006; 27(5):485-534. DOI: 10.1210/er.2005-9998. View

Barbarino A, Colasanti S, Corsello S, Satta M, Della Casa S, Rota C . Dexamethasone inhibition of interferon-alpha 2-induced stimulation of cortisol and growth hormone secretion in chronic myeloproliferative syndrome. J Clin Endocrinol Metab. 1995; 80(4):1329-32. DOI: 10.1210/jcem.80.4.7714107. View

Lisker-Melman M, Di Bisceglie A, Usala S, Weintraub B, Murray L, Hoofnagle J . Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 1992; 102(6):2155-60. DOI: 10.1016/0016-5085(92)90348-3. View

Capuron L, Raison C, Musselman D, Lawson D, Nemeroff C, Miller A . Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry. 2003; 160(7):1342-5. DOI: 10.1176/appi.ajp.160.7.1342. View

Vitale G, van Eijck C, van Koetsveld Ing P, Erdmann J, Speel E, van der Wansem Ing K . Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg. 2007; 246(2):259-68. PMC: 1933574. DOI: 10.1097/01.sla.0000261460.07110.f2. View

Darnell Jr J . STATs and gene regulation. Science. 1997; 277(5332):1630-5. DOI: 10.1126/science.277.5332.1630. View

Dafny N, Yang P . Interferon and the central nervous system. Eur J Pharmacol. 2005; 523(1-3):1-15. DOI: 10.1016/j.ejphar.2005.08.029. View

Carella C, Mazziotti G, Amato G, Braverman L, Roti E . Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004; 89(8):3656-61. DOI: 10.1210/jc.2004-0627. View

10.

Barreca T, Picciotto A, Franceschini R, Varagona G, Garibaldi A, Valle F . Sex hormones and sex hormone-binding globulin in males with chronic viral hepatitis during recombinant interferon-alpha 2b therapy. J Interferon Res. 1993; 13(3):209-11. DOI: 10.1089/jir.1993.13.209. View

11.

Corssmit E, Heijligenberg R, Endert E, Ackermans M, Sauerwein H, Romijn J . Endocrine and metabolic effects of interferon-alpha in humans. J Clin Endocrinol Metab. 1996; 81(9):3265-9. DOI: 10.1210/jcem.81.9.8784081. View

12.

Pestka S, Krause C, Walter M . Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004; 202:8-32. DOI: 10.1111/j.0105-2896.2004.00204.x. View

13.

Bekisz J, Schmeisser H, Hernandez J, Goldman N, Zoon K . Human interferons alpha, beta and omega. Growth Factors. 2004; 22(4):243-51. DOI: 10.1080/08977190400000833. View

14.

Then Bergh F, Kumpfel T, Yassouridis A, Lechner C, Holsboer F, Trenkwalder C . Acute and chronic neuroendocrine effects of interferon-beta 1a in multiple sclerosis. Clin Endocrinol (Oxf). 2007; 66(2):295-303. DOI: 10.1111/j.1365-2265.2006.02725.x. View

15.

Takeda K, Akira S . STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 2000; 11(3):199-207. DOI: 10.1016/s1359-6101(00)00005-8. View

16.

Yamaguchi M, Koike K, Matsuzaki N, Yoshimoto Y, Taniguchi T, Miyake A . The interferon family stimulates the secretions of prolactin and interleukin-6 by the pituitary gland in vitro. J Endocrinol Invest. 1991; 14(6):457-61. DOI: 10.1007/BF03346841. View

17.

Mazziotti G, Sorvillo F, Stornaiuolo G, Rotondi M, Morisco F, Ruberto M . Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest. 2002; 25(7):624-30. DOI: 10.1007/BF03345087. View

18.

Morris D, Grossman A . The medical management of Cushing's syndrome. Ann N Y Acad Sci. 2002; 970:119-33. DOI: 10.1111/j.1749-6632.2002.tb04418.x. View

19.

Plockinger U, Kruger D, Bergk A, Weich V, Wiedenmann B, Berg T . Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. Am J Gastroenterol. 2007; 102(12):2724-31. DOI: 10.1111/j.1572-0241.2007.01445.x. View

20.

Romanowski W, Braczkowski R, Kosiewicz J, Korzonek I, Nowakowska-Zajdel E, Muc-Wierzgon M . Changes in growth hormone (GH) messenger RNA (GH mRNA) expression in the rat anterior pituitary after single interferon (IFN) alpha administration. Endokrynol Pol. 2006; 57(5):482-6. View